A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
about
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.Current and future approaches for control of graft-versus-host disease.Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo.Management of acute graft-versus-host disease in children.Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.How I treat refractory acute GVHD.Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodiesAcute graft-versus-host disease: new treatment strategies.Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Immune tolerance and transplantation.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkMycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease.
P2860
Q33497983-E19C2E1E-53F0-4B26-82A2-3B9F868EDAF7Q33642625-FF189791-178B-460D-AF0B-0DA7405FC196Q33756801-62C28D7B-BD70-4471-8DA7-1D21669AC74FQ33838584-2C91EA27-D840-4B67-ACBD-F19DE663BBB3Q34489151-F2129697-6400-4956-96E5-E4DFB0AB7F00Q35583009-E41B0742-4086-4FCF-9014-06892CBB2C10Q35760517-88677302-02E3-4821-A7E1-DE4C42EF96D2Q35828633-484402DC-042B-4B97-839C-21739AD00B8CQ36904078-50397E93-AEE0-4104-B60B-ADD5BC83F976Q37106206-DD1DB4DD-8BD0-4FF7-8E67-44C07CD58CF6Q37610714-FB70F95F-0734-4BEC-87C5-73F643558593Q37739028-E06DB792-4DA1-43F2-9C70-5BA8DF4A8158Q37810286-8F58C6CF-B40C-4F91-BDAA-F94532F220CFQ37851519-167E46EE-7389-42DA-8B5A-BDD4B02D4408Q37993738-07ABB8A1-16D1-4431-8ADA-8E0593ECAB32Q38064621-4C94C8E0-FB50-4C35-8868-5267D2EAFB84Q38066586-A7B2895D-7A82-40CA-8189-58723230F433Q42149848-1B11ED67-08A6-4C4D-BAAA-370799791BC5Q43273885-353C91D8-3B1D-4208-80D1-E3EBAD108BD6Q50041876-25DC55AA-C829-40B1-8FBA-26E6F8720802Q50044411-EBCCDDF9-E826-4075-986C-86864094A52D
P2860
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A phase II multicenter study o ...... ute graft-versus-host disease.
@en
A phase II multicenter study o ...... ute graft-versus-host disease.
@nl
type
label
A phase II multicenter study o ...... ute graft-versus-host disease.
@en
A phase II multicenter study o ...... ute graft-versus-host disease.
@nl
prefLabel
A phase II multicenter study o ...... ute graft-versus-host disease.
@en
A phase II multicenter study o ...... ute graft-versus-host disease.
@nl
P2093
P50
P1476
A phase II multicenter study o ...... ute graft-versus-host disease.
@en
P2093
Claudio Anasetti
Hanna Khoury
Haydar Frangoul
James Lowder
Keith R Jerome
Laura Johnston
Pablo Parker
Paul A Carpenter
Paul Martin
Peter Westervelt
P304
P356
10.1016/J.BBMT.2005.03.002
P577
2005-06-01T00:00:00Z